Navigation Links
Transcept Pharmaceuticals to Report First Quarter 2009 Results
Date:5/5/2009

RICHMOND, Calif., May 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its first quarter 2009 on Wednesday, May 13, 2009, after market close.

A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on May 13, 2009 and will be hosted by Glenn A. Oclassen, President & Chief Executive Officer and Thomas P. Soloway, Senior Vice President & Chief Financial Officer.

To participate in the conference call, please dial 877-856-1965 (USA) or 719-325-4809 (International). In addition, a dial-up replay of the conference call will be available from May 13, 2009 at 8:00 p.m. ET (5:00 p.m. PT) through May 27, 2009. The replay telephone number is 888-203-1112 (USA) or 719-457-0820 (International), Replay Passcode: 4401678.

A live webcast of the call will also be available from the Investors section on the corporate web site at www.transcept.com. A webcast replay can be accessed on the corporate web site beginning May 13, 2009 at the same time as the conference call and will remain on the site through May 27, 2009.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company res
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... 2 Cardinal Health today...ny,s board of directors, effective immediately. ,...e president and president of global pharmaceutical...e with the company at the close of its merger with...ering-Plough, Cox served as president of Pharmacia...
(Date:12/2/2009)...ND, Sweden, December 2 DermaGen AB...and wound healing company "Pergamum" -,today annou...ts from a,clinical Phase I/IIa study. DermaGen AB ...treatment for atopic dermatitis. Atopic dermatitis...skin and the skin,s weakened barrier,function make...
(Date:12/2/2009)...sreal, December 2 Cardio...g developer of advanced,cardiovascular surgery tec...of Directors approved a one-for-three forward stoc...to Cardio Vascular Medical Device shareholders. ,...he estimated date the stock,split will be payable ...
Breaking Medicine Technology:Cardinal Health Names Carrie Cox to Board of Directors 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4Cardio Vascular Medical Device Announces Forward Stock Split 2Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30 28th 29 Anniversary Gala During First Visit to Long Island 47945 1Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30 28th 29 Anniversary Gala During First Visit to Long Island 47945 2Advances in Medical Technology Identified as a Primary Driver of Increased Costs 47943 1Advances in Medical Technology Identified as a Primary Driver of Increased Costs 47943 2Advances in Medical Technology Identified as a Primary Driver of Increased Costs 47943 3Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 1Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 2Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 3
... Nov. 3 Mpex Pharmaceuticals, Inc. today,announce...ith MP-376 for,use as a maintenance therapy in red...patients with chronic obstructive pulmonary diseas...n of levofloxacin,inhalation solution., The Phase...cebo-controlled study (Mpex 302) is expected to en...
...percent of patients achieve undetectable viral loa...eatment with standard of care, SAN FRANCISCO, Nov...TMC435, an investigational protease inhibitor (PI)... of chronic hepatitis C virus,(HCV) infection. Tib...es,including a late-breaker poster on the proof-of...
Other Medicine Technology:Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 2Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5
(Date:12/2/2009)... A team of Kendall Hunt authors earned the 2... at the recent National Association for Gifted Chi...mber 5-7, 2009. , Dubuque... Hunt authors earned the 2009 Gifted Child Quarter...Association for Gifted Children’s annual con...
(Date:12/2/2009)... Today,s Washington Post Highlights Dangers ...-- If the Catholic bishops have their way, many...ake for granted may be under threat. The pressure...ebate over healthcare reform has been widely repor...ns of the likely impact if that pressure to influe...
(Date:12/2/2009)...uspected in birth defect that affects male urethra...(HealthDay News) -- Male babies of women who use i...pregnancy appear to be at increased risk for a bir..., This birth defect, which affects about two of...ning of the urethra, the tube that carries urine f...
(Date:12/2/2009)... seem like unlikely heroes in the battle against d...sects already used to study dozens of human disea...g that fruit flies can be used as a simpler and mo...s of cocaine and other drugs of abuse on the brain...oscience , a new monthly journal. , Andrew Ewin...
(Date:12/2/2009)... MyCareTeam, Inc., a leading vendor of Inter... released the newest version of its software offer...ongestive heart failure and weight management capa...toring features. , Acto...., a leading vendor of Internet-based chronic dise...
Breaking Medicine News(10 mins):Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure 2
...n, http://www.pet-screen.com, a,U.K.-based compa...es,attacking pets, has made a generous donation to... global effort to cure canine cancer. PetScreen ha...er, while immediately seeking treatment advancemen...
...on to Postal Service Social Awareness Stamp,Series...ue a stamp next year to help raise awareness about...ss stamp series, Postmaster General John,Potter an...reness commemorative stamp, we,ll ask,Americans to...
...Medicare plans in 90 cities will,be recognized for...dical,and Part D prescription drug benefits for se...s were selected from over 200 Medicare Advantage,m...to HealthMetrix Research Inc. president Alan Mitte...
...ix Pharmaceuticals, a privately,held biotechnology...orphan-,designated tumor suppressor disorder neuro...nounced that Allan E. Rubenstein, MD, Chief Execut...,at the New York Palace Hotel. Dr. Rubenstein will...
...children with heart disease, a population already ... , More than 25 percent of children with congenit...ese, say researchers from The Childrens Hospital o...e rate found in the general population, the resear...
...tigators from the University of Massachusetts Medi...ype 1 diabetes with dual grants from the Juvenile ...a Foundation. The grants, of $150,000 each, will s...ine and professor of medicine and molecular medici...
Other Medicine News:Health News:PetScreen Supports Morris Animal Foundation Canine Cancer Campaign; Co-Sponsors Two Canine Cancer Studies 2Health News:Alzheimer's Disease to be Highlighted on Stamp Next Year 2Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 2Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 3Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 4Health News:NexGenix Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Obesity common in children with heart disease 2Health News:UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation 2
Gigli (Olivecrona) Wire Saws
Galt Skull Trephine
Cone Skull Punch
Greenberg Pattie Tray
Medicine Products: